

World Journal of *Gastroenterology*

World J Gastroenterol 2017 May 7; 23(17): 3011-3194



**EDITORIAL**

- 3011** Esophagitis and its causes: Who is "guilty" when acid is found "not guilty"?

Grossi L, Ciccaglione AF, Marzio L

- 3017** Checkpoint inhibitors in gastrointestinal cancers: Expectations and reality

Kourie HR, Tabchi S, Ghosn M

FRONTIER

- 3022** BRAF inhibitor treatment of melanoma causing colonic polyps: An alternative hypothesis

Kelleher FC, Callaghan G, Gallagher C, O'Sullivan H

REVIEW

- 3030** Genes, emotions and gut microbiota: The next frontier for the gastroenterologist

Panduro A, Rivera-Iñiguez I, Sepulveda-Villegas M, Roman S

- 3043** Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury

Qin CC, Liu YN, Hu Y, Yang Y, Chen Z

ORIGINAL ARTICLE**Basic Study**

- 3053** CXCR7/CXCL12 axis is involved in lymph node and liver metastasis of gastric carcinoma

Xin Q, Zhang N, Yu HB, Zhang Q, Cui YF, Zhang CS, Ma Z, Yang Y, Liu W

- 3066** Low-grade slightly elevated and polypoid colorectal adenomas display differential β -catenin-TCF/LEF activity, c-Myc, and cyclin D1 expression

Yang TW, Gao YH, Ma SY, Wu Q, Li ZF

Retrospective Cohort Study

- 3077** Pancreaticoduodenectomy in patients ≥ 75 years of age: Are there any differences with other age ranges in oncological and surgical outcomes? Results from a tertiary referral center

Paiella S, De Pastena M, Pollini T, Zancan G, Ciprani D, De Marchi G, Landoni L, Esposito A, Casetti L, Malleo G, Marchegiani G, Tuveri M, Marrano E, Maggino L, Secchettin E, Bonamini D, Bassi C, Salvia R

Retrospective Study

- 3084** New flexible endoscopic controlled stapler technique for the treatment of Zenker's diverticulum: A case series

Wilmsen J, Baumbach R, Stüker D, Weingart V, Nesper F, Gölder SK, Pfundstein C, Nötzel EC, Rösch T, Faiss S

- 3092** Comparison of imaging-based and pathological dimensions in pancreatic neuroendocrine tumors
Paiella S, Impellizzeri H, Zanolini E, Marchegiani G, Miotto M, Malpaga A, De Robertis R, D'Onofrio M, Rusev B, Capelli P, Cingarlini S, Butturini G, Davi MV, Amodio A, Bassi C, Scarpa A, Salvia R, Landoni L

- 3099** Octogenarian liver grafts: Is their use for transplant currently justified?
Jiménez-Romero C, Cambra F, Caso O, Manrique A, Calvo J, Marcacuzco A, Rioja P, Lora D, Justo I

- 3111** Rate of local tumor progression following radiofrequency ablation of pathologically early hepatocellular carcinoma
Hao Y, Numata K, Ishii T, Fukuda H, Maeda S, Nakano M, Tanaka K

- 3122** Prognostic value of the neutrophil-to-lymphocyte ratio for hepatocellular carcinoma patients with portal/hepatic vein tumor thrombosis
Li SH, Wang QX, Yang ZY, Jiang W, Li C, Sun P, Wei W, Shi M, Guo RP

Clinical Trials Study

- 3133** Diagnostic value of gadobenate dimeglumine-enhanced hepatocyte-phase magnetic resonance imaging in evaluating hepatic fibrosis and hepatitis
Li XM, Chen Z, Xiao EH, Shang QL, Ma C

Observational Study

- 3142** Consequences of metabolic syndrome on postoperative outcomes after pancreaticoduodenectomy
Zarzavadjian Le Bian A, Fuks D, Chopinet S, Gaujoux S, Cesaretti M, Costi R, Belgaumkar AP, Smadja C, Gayet B
- 3150** Effect of a counseling-supported treatment with the Mediterranean diet and physical activity on the severity of the non-alcoholic fatty liver disease
Gelli C, Tarocchi M, Abenavoli L, Di Renzo L, Galli A, De Lorenzo A

Prospective Study

- 3163** Cost-effectiveness of enhanced liver fibrosis test to assess liver fibrosis in chronic hepatitis C virus and alcoholic liver disease patients
Soto M, Sampietro-Colom L, Lasalvia L, Mira A, Jiménez W, Navasa M
- 3174** Impact of gastroesophageal reflux control through tailored proton pump inhibition therapy or fundoplication in patients with Barrett's esophagus
Baldaque-Silva F, Vieth M, Debel M, Håkanson B, Thorell A, Lunet N, Song H, Mascarenhas-Saraiva M, Pereira G, Lundell L, Marschall HU
- 3184** Comparison of endoscopic ultrasound, computed tomography and magnetic resonance imaging in assessment of detailed structures of pancreatic cystic neoplasms
Du C, Chai NL, Linghu EQ, Li HK, Sun LH, Jiang L, Wang XD, Tang P, Yang J

LETTER TO THE EDITOR

- 3193** Efficacy and safety of stellate ganglion block in chronic ulcerative colitis

Lipov E, Candido K

Contents

World Journal of Gastroenterology
Volume 23 Number 17 May 7, 2017

ABOUT COVER

Editorial board member of *World Journal of Gastroenterology*, Maurizio Degiuli, FRCS (Gen Surg), MD, PhD, Associate Professor, Head, Department of Oncology, University of Turin, School of Medicine, San Luigi University Hospital, Orbassano- Turin 10043, Italy

AIMS AND SCOPE

World Journal of Gastroenterology (*World J Gastroenterol*, *WJG*, print ISSN 1007-9327, online ISSN 2219-2840, DOI: 10.3748) is a peer-reviewed open access journal. *WJG* was established on October 1, 1995. It is published weekly on the 7th, 14th, 21st, and 28th each month. The *WJG* Editorial Board consists of 1375 experts in gastroenterology and hepatology from 68 countries.

The primary task of *WJG* is to rapidly publish high-quality original articles, reviews, and commentaries in the fields of gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, hepatobiliary surgery, gastrointestinal oncology, gastrointestinal radiation oncology, gastrointestinal imaging, gastrointestinal interventional therapy, gastrointestinal infectious diseases, gastrointestinal pharmacology, gastrointestinal pathophysiology, gastrointestinal pathology, evidence-based medicine in gastroenterology, pancreatology, gastrointestinal laboratory medicine, gastrointestinal molecular biology, gastrointestinal immunology, gastrointestinal microbiology, gastrointestinal genetics, gastrointestinal translational medicine, gastrointestinal diagnostics, and gastrointestinal therapeutics. *WJG* is dedicated to become an influential and prestigious journal in gastroenterology and hepatology, to promote the development of above disciplines, and to improve the diagnostic and therapeutic skill and expertise of clinicians.

INDEXING/ABSTRACTING

World Journal of Gastroenterology (*WJG*) is now indexed in Current Contents[®]/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch[®]), Journal Citation Reports[®], Index Medicus, MEDLINE, PubMed, PubMed Central, Digital Object Identifier, and Directory of Open Access Journals. The 2015 edition of Journal Citation Reports[®] released by Thomson Reuters (ISI) cites the 2015 impact factor for *WJG* as 2.787 (5-year impact factor: 2.848), ranking *WJG* as 38 among 78 journals in gastroenterology and hepatology (quartile in category Q2).

FLYLEAF

I-IX Editorial Board

EDITORS FOR THIS ISSUE

Responsible Assistant Editor: *Xiang Li*
Responsible Electronic Editor: *Fen-Fen Zhang*
Proofing Editor-in-Chief: *Lian-Sheng Ma*

Responsible Science Editor: *Ze-Mao Gong*
Proofing Editorial Office Director: *Jin-Lei Wang*

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORS-IN-CHIEF
Damian Garcia-Olmo, MD, PhD, Doctor, Professor, Surgeon, Department of Surgery, Universidad Autonoma de Madrid; Department of General Surgery, Fundacion Jimenez Diaz University Hospital, Madrid 28040, Spain

Stephen C Strom, PhD, Professor, Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Stockholm 141-86, Sweden

Andrzej S Tarnawski, MD, PhD, DSc (Med), Professor of Medicine, Chief Gastroenterology, VA Long Beach Health Care System, University of California, Irvine, CA, 5901 E. Seventh Str., Long Beach,

CA 90822, United States

EDITORIAL BOARD MEMBERS
All editorial board members resources online at <http://www.wjgnet.com/1007-9327/editorialboard.htm>

EDITORIAL OFFICE
Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>

<http://www.wjgnet.com>

PUBLICATION DATE
May 7, 2017

COPYRIGHT
© 2017 Baishideng Publishing Group Inc. Articles published by this Open-Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

SPECIAL STATEMENT
All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

INSTRUCTIONS TO AUTHORS
Full instructions are available online at <http://www.wjgnet.com/bpg/gerinfo/204>

ONLINE SUBMISSION
<http://www.f6publishing.com>

Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury

Chao-Chao Qin, Yan-Ning Liu, Ying Hu, Ying Yang, Zhi Chen

Chao-Chao Qin, Yan-Ning Liu, Ying Hu, Ying Yang, Zhi Chen, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang Province, China

Chao-Chao Qin, Yan-Ning Liu, Ying Hu, Ying Yang, Zhi Chen, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, Zhejiang Province, China

Author contributions: All authors contributed to this paper; Qin CC, Liu YN and Chen Z contributed to study conception, literature review and analysis, and drafting and critical revision of the manuscript; Hu Y and Yang Y contributed to literature review and analysis and figure drawing.

Supported by the State 12th 5-Year Plan S&T Projects of China, No. 2012ZX10002007; and National Natural Science Foundation of China, No. 81272679, No. 81470851.

Conflict-of-interest statement: The authors declare that there are no conflicts of interest related to this study.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

Manuscript source: Unsolicited manuscript

Correspondence to: Dr. Zhi Chen, Professor, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, Zhejiang University School of Medicine, 866 Yuhong Road, Hangzhou 310003, Zhejiang Province, China. zjuchenzhi@zju.edu.cn
Telephone: +86-571-87236579
Fax: +86-571-87068731

Received: November 1, 2016

Peer-review started: November 3, 2016

First decision: December 19, 2016

Revised: January 11, 2017

Accepted: February 8, 2017

Article in press: February 8, 2017

Published online: May 7, 2017

Abstract

Macrophage inflammatory protein (MIP)-2 is one of the CXC chemokines and is also known as chemokine CXC ligand (CXCL2). MIP-2 affects neutrophil recruitment and activation through the p38 mitogen-activated-protein-kinase-dependent signaling pathway, by binding to its specific receptors, CXCR1 and CXCR2. MIP-2 is produced by a variety of cell types, such as macrophages, monocytes, epithelial cells, and hepatocytes, in response to infection or injury. In liver injury, activated Kupffer cells are known as the major source of MIP-2. MIP-2-recruited and activated neutrophils can accelerate liver inflammation by releasing various inflammatory mediators. Here, we give a brief introduction to the basic molecular and cellular sources of MIP-2, and focus on its physiological and pathological functions in acute liver injury induced by concanavalin A, lipopolysaccharides, irradiation, ischemia/reperfusion, alcohol, and hypoxia, and hepatectomy-induced liver regeneration and tumor colorectal metastasis. Further understanding of the regulatory mechanisms of MIP-2 secretion and activation may be helpful to develop MIP-2-targeted therapeutic strategies to prevent liver inflammation.

Key words: Macrophage inflammatory protein-2; Liver injury; Polymorphonuclear neutrophils; Macrophages; Inflammation

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Macrophage inflammatory protein (MIP)-2

is produced by a variety of cell types in response to infection or injury, and affects neutrophil recruitment and activation by binding to chemokine CXC receptor (CXCR)1 and CXCR2. MIP-2 plays a complex dual role in the development of liver diseases by mediating liver inflammation at a high concentration and promoting liver regeneration at a low concentration. Here, we review its physiological and pathological functions in various types of liver damage. Further understanding of the regulatory mechanisms of MIP-2 may be helpful to develop MIP-2-targeted therapeutic strategies.

Qin CC, Liu YN, Hu Y, Yang Y, Chen Z. Macrophage inflammatory protein-2 as mediator of inflammation in acute liver injury. *World J Gastroenterol* 2017; 23(17): 3043-3052 Available from: URL: <http://www.wjgnet.com/1007-9327/full/v23/i17/3043.htm> DOI: <http://dx.doi.org/10.3748/wjg.v23.i17.3043>

INTRODUCTION

The chemokine family with its ability to mediate leukocyte chemotaxis can be classified into four subgroups according to the polypeptide chain cysteine location: C, CC, CXC, and CX3C^[1,2]. To date, about 50 chemokines that exhibit various physiological and pathological properties have been discovered, and most of them belong to the CC and CXC families^[3]. Macrophage inflammatory protein (MIP)-2, also known as CXC ligand (CXCL)2, is one of the CXC chemokines. It assists in the recruitment of polymorphonuclear neutrophils (PMNs) to sites of injury or infection and thereby modulates immune and inflammatory responses.

MIP-2 is released by a variety of cells in response to infection or injury, and was originally detected in macrophages as a part of their response to inflammatory stimuli. Kupffer cells contribute as potent effectors of inflammation in acute liver injury^[4]. In contrast to Kupffer-cell-sufficient mice, Kupffer-cell-ablated mice are resistant to lipopolysaccharide (LPS)-induced mortality and acute liver injury^[5]. Accumulation of neutrophils, which may drive inflammation in liver injury by releasing cytokines, in the liver of Kupffer-cell-ablated mice is significantly reduced. Since MIP-2 and its related molecules regulate neutrophil infiltration and microabscess formation, further understanding of MIP-2 function and its signaling network may provide new ideas for control of liver inflammation. The present review summarizes the basic molecular and cellular sources of MIP-2, and focuses on MIP-2 production and function in acute liver injury.

BASIC MOLECULAR AND RECEPTORS OF MIP-2

The murine (mu) MIP-2 genomic clone has four exons

and three introns, which is the typical structure of platelet factor (PF)4 chemokine sub-family^[6-8]. Murine keratinocyte chemoattractant (KC)^[9] and rat gene product/cytokine-induced neutrophil chemoattractant^[10] are involved in the sub-family^[6]. There are many human homologs of rodent MIP-2, including human platelet basic protein^[11], human growth-related oncogenes/melanoma growth stimulating activity, MIP-2 α , and MIP-2 β ^[6,12]. Although MIP-2 is a distinct member of the PF4 family, its sequence is closely related to that of the growth-related oncogene KC cytokines^[12]. MIP-2 γ is a novel CXC chemokine from a human dendritic cell cDNA library, and has no known ELR motif and shares greatest homology with MIP-2 α/β . Murine MIP-2 γ is highly homologous to human MIP-2 γ ^[13].

MIP-2 family members are potent chemotactic factors for neutrophils. MIP-2 α/β affect neutrophil recruitment and activation through the p38 mitogen-activated protein kinase (MAPK)-dependent signaling pathway, by binding to two specific receptors belonging to the G-protein-coupled receptor family, CXC chemokine receptor (CXCR)1 and CXCR2^[14]. MIP-2 γ can mediate neutrophil recruitment by binding to a novel CXC chemokine receptor, other than CXCR1 or CXCR2^[13].

MIP-2 SECRETING CELLS

MIP-2 is produced by a variety of cell types, such as macrophages, monocytes, epithelial cells, and hepatocytes, in response to infection or injury^[14]. In liver injury, activated Kupffer cells are the major source of MIP-2. Lentsch *et al.*^[15] and Mosher *et al.*^[16] reported that the level of plasma MIP-2 in GdCl₃-pretreated mice, in which Kupffer cell activity was inhibited, was significantly reduced in a model of hepatic ischemia/reperfusion (IR) injury. The extent of liver injury and neutrophil infiltration was also significantly decreased in GdCl₃-treated mice, which might have been associated with the decreased levels of MIP-2. Kupffer cell blockade by GdCl₃ treatment significantly reduced liver MIP-2 gene expression and liver inflammation after the administration of high doses of adenovirus vectors, which can induce innate immune responses in mice^[17].

The production of MIP-2 is regulated by multiple factors. Synthesis of chemokines is regulated at the transcriptional level by signaling through Toll-like receptor (TLR)2, TLR3, and TLR4 in response to diverse pathogens^[18]. MIP-2 production can be effectively inhibited in LPS-stimulated mouse peritoneal macrophage cell line, RAW 264.7, through downregulating mRNA accumulation and protein expression of membrane TLR4/mCD14. This indicates that upstream inhibition of the TLR4/CD14-mediated inflammation pathway may be an effective therapeutic approach for attenuating damaging immune activation^[19]. So *et al.*^[20] found that *Scutellariae Radix* and *Liriodopsis Tuber* (SL) significantly inhibited the release of MIP-2 in LPS-induced RAW 264.7 cells. Another

study showed that histone deacetylase modulated MIP-2 secretion. The secretion of MIP-2 was enhanced in LPS-stimulated and interleukin (IL)-1 β -stimulated rat small intestinal epithelial cells by butyrate, a bacterial metabolite, through modulating histone acetylase. Furthermore, acetylation of histones by a specific inhibitor of histone deacetylase enhanced MIP-2 expression in IL-1 β -stimulated cells^[21].

MIP-2 MEDIATES INFLAMMATION BY NEUTROPHIL RECRUITMENT

Neutrophils are the most abundant circulating white blood cell type and a major innate immune cell subset in humans. Inappropriate activation and recruitment of neutrophils to the microvasculature contributes to the pathological manifestations of many types of inflammation^[22]. In the liver, the recruitment of neutrophils to the sites of injury or infection is MIP-2 dependent.

MIP-2 as potent neutrophil chemotactic factor

MIP-2 is a potent chemotactic and activation factor of neutrophils and plays a critical role in neutrophil recruitment during acute inflammation in rat disease models^[23]. It was found that corneal MIP-2 levels were correlated with persistence of PMNs in the cornea of susceptible (cornea perforates) mice after *Pseudomonas aeruginosa* challenge. By treating systemically with recombinant MIP-2, the number of corneal PMNs was significantly increased, and resulted in exacerbated corneal disease in resistant (cornea heals) mice^[24]. In the cecal ligation and puncture (CLP) model for sepsis, MIP-2 mRNA and protein were significantly upregulated after CLP in mice, while the neutralization of MIP-2 by anti-MIP-2 antibody reduced peritoneal PMN migration. Mercer-Jones *et al.*^[25] also found that mast cells were necessary for PMN migration into the peritoneum, and significantly less migration of PMNs into the peritoneal cavity in the mast-cell-deficient mice after MIP-2 injection. MIP-2 was also involved in neutrophil recruitment in the central nervous system during experimental bacterial meningitis. The kinetics of MIP-2 mRNA expression are paralleled by the recruitment of inflammatory cells and disease severity. Blocking of MIP-2 bioactivity by anti-MIP-2 antibodies results in significantly decreased neutrophil influx^[26,27]. When injected *in vivo* as recombinant chemokines, KC and MIP-2 in models of inflammation, can cause neutrophil influx^[28,29]. The results of other studies have highlighted MIP-2 as the major chemoattractant^[29]. In liver injury, neutralizing KC and MIP-2 result in less neutrophil extravasation and reduce neutrophil-induced injury in a mouse model of cholestatic liver damage^[30]. Further studies have shown that neutrophil extravasation into the parenchyma requires a chemotactic signal such as MIP-2 and KC from macrophages, hepatocytes, or

already-extravasated neutrophils. Tissue damage and cell necrosis often result in the release of damage-associated molecular patterns, which lead to intercellular adhesion molecule-1 upregulation on sinusoidal endothelial cells. Neutrophils are then recruited to endothelial cells or hepatocytes *via* a β 2 integrin macrophage antigen (Mac)-1-dependent adhesion mechanism^[24,31-35].

Neutrophils drive inflammation in liver injury by releasing inflammatory mediators

The recruitment of neutrophils to target cells triggers full activation of the neutrophils with a long-lasting adherence dependent oxidative stress and degranulation. The activated neutrophils release various inflammatory mediators, including proteolytic enzymes, lipocalin 2, arachidonic acid metabolites, and reactive oxygen species (ROS)^[36-40].

Several mechanisms of neutrophil-mediated tissue injury have been proposed. One is the production of reactive oxygen intermediates, which may directly induce hepatic endothelial damage or indirectly induce tissue injury by triggering other inflammatory mediators^[41,42]. Neutrophil-derived proteases facilitate extravasation and are involved in the regulation of inflammatory mediator production. The adhesion *via* Mac-1 triggers superoxide formation by NADPH oxidase and degranulation with the release of myeloperoxidase (MPO) and proteases^[43]. Optimal oxygen-dependent microbicidal activity depends on MPO as the critical enzyme for the generation of hypochlorous acid and other toxic oxygen products. Although the proteases appear to be mainly involved in the promotion of chemokines, hydrogen peroxide, and MPO-derived hypochlorite, they also induce intracellular oxidative stress in hepatocytes and eventually cause oncotic necrosis^[44,45].

Liver dysfunction and cell injury induced by neutrophils have been demonstrated in several experimental models including hepatic IR injury^[46], endotoxic shock^[47], sepsis^[48], alcoholic hepatitis^[49], obstructive cholestasis^[50], LPS injury^[51], remote organ trauma^[52], and concanavalin A (ConA)-induced liver injury^[53]. Neutrophil-mediated injury was also demonstrated in two-hit models of IR injury or drug hepatotoxicity in combination with endotoxemia^[54].

Recruitment of neutrophils to the sites of liver injury is MIP-2 dependent, and the activated neutrophils can accelerate liver inflammation by releasing various inflammatory mediators.

MIP-2 PRODUCTION IN MURINE MODELS OF ACUTE LIVER INJURY

MIP-2 plays an important role in the progression of inflammation. Some clinical studies have shown the correlation between MIP-2 and organ inflammation,

such as in pneumonia^[55]. However, there are few clinical reports about the effect of MIP-2 in acute liver injury. At present, most of the studies on the mechanism of MIP-2 secretion and regulation in acute liver injury have been in animal models.

ConA-induced acute liver injury

ConA-induced hepatitis is a well-characterized form of autoimmune hepatic damage in murine models, with a pathophysiology similar to that of human viral and autoimmune hepatitis^[56]. T cells, particularly CD4⁺ cells, play an essential role in the development of ConA-induced hepatitis. Activated T lymphocyte infiltration induces hepatocyte apoptosis and necrosis and provokes production and secretion of a series of proinflammatory cytokines, such as tumor necrosis factor (TNF)- α , interferon (IFN)- γ , IL-6 and ROS^[57,58]. Besides that, MIP-2 is another major mediator of ConA-mediated inflammation^[53]. The infiltration of F4/80⁺ macrophages and the mRNA level of MIP-2 were dramatically increased in the liver of ConA-treated mice^[53,54]. The plasma MIP-2 level was elevated and reached a peak value at 2 h after ConA injection^[59]. Pretreatment with anti-MIP-2 antibody suppressed the elevation of plasma alanine aminotransferase (ALT) levels and reduce hepatic necrosis in a dose-dependent manner^[20,32,60]. Hepatic infiltration of neutrophils was also attenuated by MIP-2 blockade^[60,61]. Another study showed that antithrombin III, an important physiological inhibitor of the coagulation cascade, prevents ConA-induced liver injury through inhibition of MIP-2 release^[59]. Our previous study showed that emodin pretreatment protects against ConA-induced liver injury in mice, and this effect may occur partially through inhibition of macrophages infiltration and activation of the p38 MAPK/nuclear factor (NF)- κ B pathway in macrophages^[53].

LPS-induced acute liver injury

LPS is one of the most potent innate immune-activating stimuli. LPS binds to TLR4 to induce macrophage activation, which results in the secretion of the CXC chemokines and proinflammatory mediators. Inflammatory cells such as neutrophils, T lymphocytes, multiple leukocyte subtypes, monocytes, eosinophils, basophils, dendritic cells, and natural killer cells can be attracted into the injured tissue sections through the portal vessels and play a pivotal role in initiating an inflammatory response^[23,62-64]. Some studies have shown that MIP-2 is one of the key mediators in LPS-induced liver injury^[65,66]. MIP-2 expression was induced in freshly isolated rat hepatocytes following treatment with LPS^[67]. The hepatic expression of chemokine mRNAs was elevated after LPS exposure, with the maximal expression of MIP-2 mRNA at 1 h after LPS treatment^[66,68]. LPS *in vivo* also induced high levels of chemokine MIP-2 mRNA in mouse liver and lung, with a concomitant increase in circulating MIP-2 protein^[69].

MIP-2 production was inhibited in LPS-stimulated RAW 264.7 though downregulation of mRNA accumulation and protein expression of TLR4^[19], indicating that TLR4 is the important receptor in LPS-induced liver injury. Further studies have shown that the LPS-induced MIP-2 production is dependent on NF- κ B activation *via* inhibition of the IKK pathway^[70-72]. Intraperitoneal injection of anti-MIP-2 antibody significantly decreases the influx of neutrophils in the liver of rats after LPS injection^[73]. Interference with MIP-2 function protects against septic liver damage, which may constitute a potential therapeutic strategy to control pathological inflammation in endotoxemia^[74].

Irradiation-induced acute liver injury

Liver is considered to be a radiosensitive organ. Radiation therapy involves the use of high-energy rays to treat local or regional malignancies. Free radicals such as ROS containing unpaired electrons are generated after irradiation in the irradiated tissue, and cells that are chemically active are prone to oxidative stress. Liver damage is a serious clinical complication of radiation therapy^[64,75]. Single dose γ -irradiation (25 Gy) focused on the liver recruits neutrophils attached to the portal vessels and to portal (myo) fibroblasts in the liver, and several chemokines may be necessary in their recruitment, adhesion, and transmigration. Rapid and early induction of expression of several chemokines and chemokine receptor CXCR2 genes in irradiated liver tissue and portal area has been observed. MIP-2 has been detected in the portal vessel walls, and CXCR2 in the portal area but not in the parenchyma^[64,76]. The induction of the mediators in cells of portal area (mainly myofibroblasts) may happen through ROS^[39].

IR-induced acute liver injury

IR-induced hepatic injury is an important clinical problem after liver resection or transplantation. Initial IR-induced hepatic injury is reported to be mediated by activated Kupffer cells without dependence on neutrophils^[77,78]. The later phase of IR injury is dependent upon hepatic neutrophil sequestration, and the subsequent increased adherence between neutrophils and endothelial cells. Depletion of neutrophils and Kupffer cells before ischemia greatly reduces reperfusion injury^[79,80]. MIP-2 is also known as an important mediator in IR-induced liver injury by regulating hepatic neutrophil accumulation^[41,42,73,81,82]. Expression of MIP-2 mRNA was induced within 3 h after reperfusion, before neutrophil accumulation in the liver, and was increased to a greater extent in the ischemic liver lobe at 9 h post-reperfusion^[15]. The anti-inflammatory cytokine IL-10 affects inflammatory reactions partly through inhibitory effects on NF- κ B. Yoshidome *et al.*^[83] found that IL-10 protects against hepatic IR injury by suppressing NF- κ B activation as well as hepatic mRNA expression and the serum level

of MIP-2. A recent study showed that Pin1, as a critical regulator for NF- κ B/DNA binding and activation, might be an important protective factor for hepatocytes against IR injury by reducing serum MIP-2 level after reperfusion^[84].

Alcohol-induced acute liver injury

Alcohol is a well-known risk factor related to liver injury. Excessive alcohol exposure leads to alcohol liver disease; a major cause of morbidity and mortality worldwide. Alcohol abuse also causes hepatic steatosis. Alcohol combination with a high-fructose diet could aggravate alcoholic fatty liver disease^[85]. The major pathogenetic factors are multifactorial and complex, involving increased hepatic *de novo* lipogenesis and triglyceride synthesis, impaired mitochondrial fatty acid β -oxidation, decreased very low-density lipoprotein secretion, and increased levels of chemokine secretion and adhesion molecule expression^[86-88].

MIP-2 also plays a potent role in alcohol-induced liver injury. In alcohol-fed male Sprague-Dawley rats, alcohol intoxication induced hepatic injury through endotoxin influx in the circulation, and stimulated the Kupffer cells to produce MIP2 and upregulated expression of adhesion molecules on hepatic cells, which resulted in altered hepatic function and hepatotoxicity by hepatic neutrophils recruitment^[89]. Nanji *et al.*^[90] showed that alcohol-induced liver injury was more severe in female than in male rats. Female rats had higher levels of endotoxin, lipid peroxidation, non-heme iron, and chemokines MCP-1 and MIP-2 after alcohol intake. The upregulation of MIP-2 in alcohol-induced liver injury has also been shown to be NF- κ B dependent^[90,91]. Inhibition of NF- κ B activation by treatment with a phenolic antioxidant, curcumin, prevented the pathological and biochemical changes induced by alcohol, and enhanced MIP-2 expression^[91,92].

Hypoxia-induced liver injury

In cellular responses to hypoxia, hypoxia-inducible factors as well as proinflammatory cytokine/chemokines are released. Oxygen consumption by hepatocytes and infiltrating inflammatory leukocytes is dramatically increased. Mice exposed to chronic intermittent hypoxia (CIH) exhibited lobular inflammation and fibrosis in the liver. CIH caused significant increases in lipid peroxidation in serum and liver, and increased hepatic levels of proinflammatory cytokines IL-1 β , IL-6 and CXC chemokine MIP-2^[93]. An *in vitro* study showed that MIP-2 expression was prominently induced by hypoxia both at the mRNA and protein level in RAW264.7 cells, while it was abolished by a mutation targeted to an NF- κ B binding site in the MIP-2 promoter, suggesting that hypoxia-induced MIP-2 expression occurs exclusively *via* the NF- κ B pathway. Further study of the mechanism by using inhibitors of signaling kinases have shown that the induction of MIP-2 is correlated with p42/p44 and

PI3 kinase but not p38 kinase signaling in hypoxia^[94].

OTHER FUNCTIONS OF MIP-2

Apart from its major role in mediating inflammation, MIP-2 also plays important roles in liver regeneration and engraftment of colorectal metastasis at extra-hepatic sites. Administration of exogenous MIP-2 after 70% hepatectomy dramatically increases hepatocyte proliferation. Inhibition of the MIP-2 receptor, CXCR2, decreases baseline hepatocyte proliferation in the setting of partial hepatectomy. These data suggest that MIP-2 is important for hepatocyte proliferation and pharmacological doses of MIP-2 after hepatic injury may accelerate hepatic regeneration^[95]. Adenovirus-mediated gene therapy or acetaminophen ingestion often produces profound hepatocellular injury. MIP-2 has a protective role in both adenovirus- and acetaminophen-mediated hepatotoxicity, suggesting that MIP-2 promotes hepatic regeneration following acute hepatic injury^[96,97]. CCR2 is the primary receptor for chemokine MCP-1, which mainly attracts macrophages to secrete MIP-2. It was shown that CCR2-deficient mice had increased hepatic toxicity after acetaminophen exposure^[98]. Further studies have shown that the properties in liver regeneration of ELR-CXC chemokines, such as MIP-2, in acetaminophen challenge are attributed mainly to the ELR motif^[77,99,100].

Other studies have demonstrated the role of MIP-2 in the hepatectomy-induced acceleration of tumor growth^[101,102]. Major liver resection often initiates rapid regeneration of the remnant liver to restore functional hepatic capacity. Besides parenchymal regeneration, hepatectomy also accelerates tumor growth in the remaining liver and remote organ sites^[6]. MIP-2 contributes to liver-resection-induced acceleration of colorectal metastasis at extrahepatic sites. Blockade of MIP-2 decreases the hepatectomy-induced increase of CXCR2 expression on tumor cells, thus attenuating the augmentation of angiogenesis and metastatic tumor growth after hepatectomy^[103]. A further study showed that liver-resection-associated MIP-2 upregulation stimulates extrahepatic tumor cell engraftment but not the growth of established metastases^[101].

MIP-2 SIGNALING PATHWAYS

A variety of cytokines and signal pathways regulate the production level of MIP-2 in macrophages (Figure 1). MIP-2 expression is partially inhibited by intradermal injection of a neutralizing antibody against IL-1, which has modest stimulus activity for MIP-2^[103]. Fas ligation induces MIP-2 expression in the liver through activation of caspase-3 and nuclear translocation of activator protein-1^[104]. The increased production of ROS by ATP-stimulated macrophages activates the signaling pathways that promote MIP-2 production, which, in turn, induces neutrophil migration^[105].




Figure 1 Molecular mechanisms involved in macrophage inflammatory protein-2 secretion of macrophages. The Figure illustrates several reciprocal molecular pathways for the secretion of MIP-2. These include: LPS-mediated induction of MIP-2, IL-6, IL-1 β , TNF- α through the NF- κ B/MAPK signaling pathway; IL-6-mediated induction of MIP-2 through the NF- κ B/MAPK signaling pathway; TNF- α -mediated induction of MIP-2 through the NF- κ B/MAPK, caspase-3 signaling pathway; FasL-mediated induction of MIP-2 through the caspase-3 signaling pathway; Ca²⁺- and ATP-mediated induction of MIP-2 through the PI3K signaling pathway; IL-1 β -mediated induction of MIP-2 through the NF- κ B/MAPK signaling pathway; IFN- γ and IL-10-mediated inhibition of MIP-2, IL-6, IL-1 β and TNF- α through the JAK/STAT3 signaling pathway; SOCS3-mediated inhibition of JAK/STAT3. MIP-2: Macrophage inflammatory protein-2; TNF- α : Tumor necrosis factor- α ; IFN- γ : Interferon- γ ; IL: Interleukin; LPS: Lipopolysaccharide.

Cotreatment with IL-17A synergistically enhances the upregulation of MIP-2 in taurocholic-acid-treated primary mouse hepatocytes, suggesting that IL-17A promotes hepatic inflammation by enhancing bile-acid-induced production of MIP-2^[106]. Treatment of RAW264.7 cells with an inhibitor of p38 attenuated the synergistic effects of C5a and MIP-2 on cells primed with muramyl dipeptide^[107]. Another study has shown that inhibiting ELR-CXC chemokines can block ELR⁺ CXC chemokines neutrophil recruitment and activation *in vitro*. In IR-induced hepatic injury, the hepatic levels of ELR⁺ chemokines, including MIP-2, were decreased in response to IFN- γ , which is known to upregulate ELR-CXC chemokines^[108]. IL-10 also shown protects against hepatic IR injury by suppressing NF- κ B activation and subsequent expression of MIP-2^[83,109].

CONCLUSION

MIP-2 plays a dual role in mediating liver inflammation and promoting liver regeneration. Liver regeneration depends on the physiological concentration of MIP-2, however, excessive elevation of MIP-2 induced by acute liver injury promotes liver inflammation by neutrophil

recruitment. An imbalance of MIP-2 secretion resulting in a disorder between the pro- and anti-inflammatory mediators may be vital in determining the outcome of liver injury. Since the signaling mechanisms of MIP-2 secretion remain to be elucidated, further understanding of the regulation mechanism of MIP-2 secretion is helpful to develop MIP-2-targeted therapeutic strategies for preventing liver inflammation.

REFERENCES

- 1 Miller MD, Krangel MS. Biology and biochemistry of the chemokines: a family of chemotactic and inflammatory cytokines. *Crit Rev Immunol* 1992; **12**: 17-46 [PMID: 1418604]
- 2 Nomiyama H, Mera A, Ohneda O, Miura R, Suda T, Yoshie O. Organization of the chemokine genes in the human and mouse major clusters of CC and CXC chemokines: diversification between the two species. *Genes Immun* 2001; **2**: 110-113 [PMID: 11393655 DOI: 10.1038/sj.gene.6363742]
- 3 Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. *N Engl J Med* 2006; **354**: 610-621 [PMID: 16467548 DOI: 10.1056/NEJMr052723]
- 4 Tsutsui H, Nishiguchi S. Importance of Kupffer cells in the development of acute liver injuries in mice. *Int J Mol Sci* 2014; **15**: 7711-7730 [PMID: 24802875 DOI: 10.3390/ijms15057711]
- 5 Imamura M, Tsutsui H, Yasuda K, Uchiyama R, Yumikura-Futatsugi S, Mitani K, Hayashi S, Akira S, Taniguchi S, Van

- Rooijen N, Tschopp J, Yamamoto T, Fujimoto J, Nakanishi K. Contribution of TIR domain-containing adapter inducing IFN- β -mediated IL-18 release to LPS-induced liver injury in mice. *J Hepatol* 2009; **51**: 333-341 [PMID: 19501931 DOI: 10.1016/j.jhep.2009.03.027]
- 6 Anisowicz A, Bardwell L, Sager R. Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells. *Proc Natl Acad Sci USA* 1987; **84**: 7188-7192 [PMID: 2890161]
- 7 Deuel TF, Keim PS, Farmer M, Heinrikson RL. Amino acid sequence of human platelet factor 4. *Proc Natl Acad Sci USA* 1977; **74**: 2256-2258 [PMID: 267922]
- 8 Doi T, Greenberg SM, Rosenberg RD. Structure of the rat platelet factor 4 gene: a marker for megakaryocyte differentiation. *Mol Cell Biol* 1987; **7**: 898-904 [PMID: 3821732]
- 9 Oquendo P, Alberta J, Wen DZ, Graycar JL, Derynck R, Stiles CD. The platelet-derived growth factor-inducible KC gene encodes a secretory protein related to platelet alpha-granule proteins. *J Biol Chem* 1989; **264**: 4133-4137 [PMID: 2917992]
- 10 Watanabe K, Konishi K, Fujioka M, Kinoshita S, Nakagawa H. The neutrophil chemoattractant produced by the rat kidney epithelioid cell line NRK-52E is a protein related to the KC/gro protein. *J Biol Chem* 1989; **264**: 19559-19563 [PMID: 2684956]
- 11 Holt JC, Harris ME, Holt AM, Lange E, Henschen A, Niewiarowski S. Characterization of human platelet basic protein, a precursor form of low-affinity platelet factor 4 and beta-thromboglobulin. *Biochemistry* 1986; **25**: 1988-1996 [PMID: 2423119]
- 12 Tekamp-Olson P, Gallegos C, Bauer D, McClain J, Sherry B, Fabre M, van Deventer S, Cerami A. Cloning and characterization of cDNAs for murine macrophage inflammatory protein 2 and its human homologues. *J Exp Med* 1990; **172**: 911-919 [PMID: 2201751]
- 13 Wolpe SD, Sherry B, Juers D, Davatelis G, Yurt RW, Cerami A. Identification and characterization of macrophage inflammatory protein 2. *Proc Natl Acad Sci USA* 1989; **86**: 612-616 [PMID: 2643119]
- 14 Rittner HL, Labuz D, Richter JF, Brack A, Schäfer M, Stein C, Mousa SA. CXCR1/2 ligands induce p38 MAPK-dependent translocation and release of opioid peptides from primary granules in vitro and in vivo. *Brain Behav Immun* 2007; **21**: 1021-1032 [PMID: 17604950 DOI: 10.1016/j.bbi.2007.05.002]
- 15 Lentsch AB, Yoshidome H, Cheadle WG, Miller FN, Edwards MJ. Chemokine involvement in hepatic ischemia/reperfusion injury in mice: roles for macrophage inflammatory protein-2 and Kupffer cells. *Hepatology* 1998; **27**: 507-512 [PMID: 9462650 DOI: 10.1002/hep.510270226]
- 16 Mosher B, Dean R, Harkema J, Remick D, Palma J, Crockett E. Inhibition of Kupffer cells reduced CXC chemokine production and liver injury. *J Surg Res* 2001; **99**: 201-210 [PMID: 11469888 DOI: 10.1006/jsre.2001.6217]
- 17 Liu Q, Zaiss AK, Colarusso P, Patel K, Haljan G, Wickham TJ, Muruve DA. The role of capsid-endothelial interactions in the innate immune response to adenovirus vectors. *Hum Gene Ther* 2003; **14**: 627-643 [PMID: 12804145]
- 18 De Filippo K, Henderson RB, Laschinger M, Hogg N. Neutrophil chemokines KC and macrophage-inflammatory protein-2 are newly synthesized by tissue macrophages using distinct TLR signaling pathways. *J Immunol* 2008; **180**: 4308-4315 [PMID: 18322244]
- 19 Lei M, Jiao H, Liu T, Du L, Cheng Y, Zhang D, Hao Y, Man C, Wang F. siRNA targeting mCD14 inhibits TNF- α , MIP-2, and IL-6 secretion and NO production from LPS-induced RAW264.7 cells. *Appl Microbiol Biotechnol* 2011; **92**: 115-124 [PMID: 21701985 DOI: 10.1007/s00253-011-3371-7]
- 20 So MH, Choi YK. Anti-Inflammatory Effect of Combination of Scutellariae Radix and Liriopeis Tuber Water Extract. *Evid Based Complement Alternat Med* 2015; **2015**: 203965 [PMID: 26604969 DOI: 10.1155/2015/203965]
- 21 Ohno Y, Lee J, Fusunyan RD, MacDermott RP, Sanderson IR. Macrophage inflammatory protein-2: chromosomal regulation in rat small intestinal epithelial cells. *Proc Natl Acad Sci USA* 1997; **94**: 10279-10284 [PMID: 9294201]
- 22 Xu R, Huang H, Zhang Z, Wang FS. The role of neutrophils in the development of liver diseases. *Cell Mol Immunol* 2014; **11**: 224-231 [PMID: 24633014 DOI: 10.1038/cmi.2014.2]
- 23 Amanzada A, Moriconi F, Mansuroglu T, Cameron S, Ramadori G, Malik IA. Induction of chemokines and cytokines before neutrophils and macrophage recruitment in different regions of rat liver after TAA administration. *Lab Invest* 2014; **94**: 235-247 [PMID: 24276236 DOI: 10.1038/labinvest.2013.134]
- 24 Cole N, Hume EB, Khan S, Garthwaite L, Conibear TC, Willcox MD. The role of CXC chemokine receptor 2 in *Staphylococcus aureus* keratitis. *Exp Eye Res* 2014; **127**: 184-189 [PMID: 25107538 DOI: 10.1016/j.exer.2014.07.016]
- 25 Mercer-Jones MA, Shrotri MS, Heinzelmann M, Peyton JC, Cheadle WG. Regulation of early peritoneal neutrophil migration by macrophage inflammatory protein-2 and mast cells in experimental peritonitis. *J Leukoc Biol* 1999; **65**: 249-255 [PMID: 10088608]
- 26 Ramos CD, Fernandes KS, Canetti C, Teixeira MM, Silva JS, Cunha FQ. Neutrophil recruitment in immunized mice depends on MIP-2 inducing the sequential release of MIP-1 α , TNF- α and LTB(4). *Eur J Immunol* 2006; **36**: 2025-2034 [PMID: 16856209 DOI: 10.1002/eji.200636057]
- 27 Feng L, Xia Y, Yoshimura T, Wilson CB. Modulation of neutrophil influx in glomerulonephritis in the rat with anti-macrophage inflammatory protein-2 (MIP-2) antibody. *J Clin Invest* 1995; **95**: 1009-1017 [PMID: 7883948 DOI: 10.1172/jci117745]
- 28 Frevert CW, Huang S, Danae H, Paulauskis JD, Kobzik L. Functional characterization of the rat chemokine KC and its importance in neutrophil recruitment in a rat model of pulmonary inflammation. *J Immunol* 1995; **154**: 335-344 [PMID: 7995953]
- 29 Zhao Z, Hyun JS, Satsu H, Kakuta S, Shimizu M. Oral exposure to cadmium chloride triggers an acute inflammatory response in the intestines of mice, initiated by the over-expression of tissue macrophage inflammatory protein-2 mRNA. *Toxicol Lett* 2006; **164**: 144-154 [PMID: 16413704 DOI: 10.1016/j.toxlet.2005.12.004]
- 30 Wintermeyer P, Cheng CW, Gehring S, Hoffman BL, Holub M, Brossay L, Gregory SH. Invariant natural killer T cells suppress the neutrophil inflammatory response in a mouse model of cholestatic liver damage. *Gastroenterology* 2009; **136**: 1048-1059 [PMID: 19056387 DOI: 10.1053/j.gastro.2008.10.027]
- 31 Orlichenko LS, Behari J, Yeh TH, Liu S, Stolz DB, Saluja AK, Singh VP. Transcriptional regulation of CXC-ELR chemokines KC and MIP-2 in mouse pancreatic acini. *Am J Physiol Gastrointest Liver Physiol* 2010; **299**: G867-G876 [PMID: 20671197 DOI: 10.1152/ajpgi.00177.2010]
- 32 Luyendyk JP, Flanagan KC, Williams CD, Jaeschke H, Slusser JG, Mackman N, Cantor GH. Tissue factor contributes to neutrophil CD11b expression in alpha-naphthylisothiocyanate-treated mice. *Toxicol Appl Pharmacol* 2011; **250**: 256-262 [PMID: 21070799 DOI: 10.1016/j.taap.2010.11.002]
- 33 Gujral JS, Liu J, Farhood A, Hinson JA, Jaeschke H. Functional importance of ICAM-1 in the mechanism of neutrophil-induced liver injury in bile duct-ligated mice. *Am J Physiol Gastrointest Liver Physiol* 2004; **286**: G499-G507 [PMID: 14563671 DOI: 10.1152/ajpgi.00318.2003]
- 34 Hasan Z, Palani K, Rahman M, Thorlacius H. Targeting CD44 expressed on neutrophils inhibits lung damage in abdominal sepsis. *Shock* 2011; **35**: 567-572 [PMID: 21330943 DOI: 10.1097/SHK.0b013e3182144935]
- 35 McDonald B, McAvoy EF, Lam F, Gill V, de la Motte C, Savani RC, Kubes P. Interaction of CD44 and hyaluronan is the dominant mechanism for neutrophil sequestration in inflamed liver sinusoids. *J Exp Med* 2008; **205**: 915-927 [PMID: 18362172 DOI: 10.1084/jem.20071765]
- 36 Kolaczowska E, Jenne CN, Surewaard BG, Thanabalasuriar A, Lee WY, Sanz MJ, Mowen K, Opdenakker G, Kubes P. Molecular mechanisms of NET formation and degradation revealed by intravital imaging in the liver vasculature. *Nat Commun* 2015; **6**:

- 6673 [PMID: 25809117 DOI: 10.1038/ncomms7673]
- 37 **Huang H**, Tohme S, Al-Khafaji AB, Tai S, Loughran P, Chen L, Wang S, Kim J, Billiar T, Wang Y, Tsung A. Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. *Hepatology* 2015; **62**: 600-614 [PMID: 25855125 DOI: 10.1002/hep.27841]
- 38 **Wree A**, Eguchi A, McGeough MD, Pena CA, Johnson CD, Canbay A, Hoffman HM, Feldstein AE. NLRP3 inflammasome activation results in hepatocyte pyroptosis, liver inflammation, and fibrosis in mice. *Hepatology* 2014; **59**: 898-910 [PMID: 23813842 DOI: 10.1002/hep.26592]
- 39 **Sultan S**, Cameron S, Ahmad S, Malik IA, Schultze FC, Hielscher R, Rave-Fränk M, Hess CF, Ramadori G, Christiansen H. Serum Lipocalin2 is a potential biomarker of liver irradiation damage. *Liver Int* 2013; **33**: 459-468 [PMID: 23331620 DOI: 10.1111/liv.12073]
- 40 **Sultan S**, Pascucci M, Ahmad S, Malik IA, Bianchi A, Ramadori P, Ahmad G, Ramadori G. LIPOCALIN-2 is a major acute-phase protein in a rat and mouse model of sterile abscess. *Shock* 2012; **37**: 191-196 [PMID: 22249220 DOI: 10.1097/SHK.0b013e31823918c2]
- 41 **Yasukawa K**, Tokuda H, Tun X, Utsumi H, Yamada K. The detrimental effect of nitric oxide on tissue is associated with inflammatory events in the vascular endothelium and neutrophils in mice with dextran sodium sulfate-induced colitis. *Free Radic Res* 2012; **46**: 1427-1436 [PMID: 22998024 DOI: 10.3109/10715762.2012.732698]
- 42 **Adam M**, Gajdova S, Kolarova H, Kubala L, Lau D, Geisler A, Ravekes T, Rudolph V, Tsao PS, Blankenberg S, Baldus S, Klinke A. Red blood cells serve as intravascular carriers of myeloperoxidase. *J Mol Cell Cardiol* 2014; **74**: 353-363 [PMID: 24976018 DOI: 10.1016/j.jmcc.2014.06.009]
- 43 **El-Benna J**, Dang PM, Gougerot-Pocidalo MA, Elbim C. Phagocyte NADPH oxidase: a multicomponent enzyme essential for host defenses. *Arch Immunol Ther Exp (Warsz)* 2005; **53**: 199-206 [PMID: 15995580]
- 44 **Schönberg M**, Reibetanz U, Rathmann S, Lessig J. Maintenance of $\alpha(1)$ -antitrypsin activity by means of co-application of hypochlorous acid-scavengers in vitro and in the supernatant of polymorphonuclear leukocytes: as a basis for a new drug delivery approach. *Biomater* 2012; **2**: 24-36 [PMID: 23507783 DOI: 10.4161/biom.19190]
- 45 **Amanzada A**, Malik IA, Nischwitz M, Sultan S, Naz N, Ramadori G. Myeloperoxidase and elastase are only expressed by neutrophils in normal and in inflamed liver. *Histochem Cell Biol* 2011; **135**: 305-315 [PMID: 21327394 DOI: 10.1007/s00418-011-0787-1]
- 46 **Guan LY**, Fu PY, Li PD, Li ZN, Liu HY, Xin MG, Li W. Mechanisms of hepatic ischemia-reperfusion injury and protective effects of nitric oxide. *World J Gastrointest Surg* 2014; **6**: 122-128 [PMID: 25068009 DOI: 10.4240/wjgs.v6.i7.122]
- 47 **Bergquist M**, Jirholt P, Nurkkala M, Rylander C, Hedenstierna G, Lindholm C. Glucocorticoid receptor function is decreased in neutrophils during endotoxemic shock. *J Infect* 2014; **69**: 113-122 [PMID: 24657243 DOI: 10.1016/j.jinf.2014.03.011]
- 48 **de Oliveira TH**, Amorin AT, Rezende IS, Santos Barbosa M, Martins HB, Brito AK, Andrade EF, Gonçalves GK, Campos GB, Silva RA, Timenetsky J, Marques LM. Sepsis induced by *Staphylococcus aureus*: participation of biomarkers in a murine model. *Med Sci Monit* 2015; **21**: 345-355 [PMID: 25630550 DOI: 10.12659/msm.892528]
- 49 **Lazaro R**, Wu R, Lee S, Zhu NL, Chen CL, French SW, Xu J, Machida K, Tsukamoto H. Osteopontin deficiency does not prevent but promotes alcoholic neutrophilic hepatitis in mice. *Hepatology* 2015; **61**: 129-140 [PMID: 25132354 DOI: 10.1002/hep.27383]
- 50 **Yang M**, Ramachandran A, Yan HM, Woolbright BL, Copple BL, Fickert P, Trauner M, Jaeschke H. Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. *Toxicol Lett* 2014; **224**: 186-195 [PMID: 24188933 DOI: 10.1016/j.toxlet.2013.10.030]
- 51 **Britt RD**, Locy ML, Tipple TE, Nelin LD, Rogers LK. Lipopolysaccharide-induced cyclooxygenase-2 expression in mouse transformed Clara cells. *Cell Physiol Biochem* 2012; **29**: 213-222 [PMID: 22415090 DOI: 10.1159/000337602]
- 52 **Jawa RS**, Quist E, Boyer CW, Shostrom VK, Mercer DW. Mesenteric ischemia-reperfusion injury up-regulates certain CC, CXC, and XC chemokines and results in multi-organ injury in a time-dependent manner. *Eur Cytokine Netw* 2013; **24**: 148-156 [PMID: 24589386 DOI: 10.1684/ecn.2014.0345]
- 53 **Xue J**, Chen F, Wang J, Wu S, Zheng M, Zhu H, Liu Y, He J, Chen Z. Emodin protects against concanavalin A-induced hepatitis in mice through inhibiting activation of the p38 MAPK-NF- κ B signaling pathway. *Cell Physiol Biochem* 2015; **35**: 1557-1570 [PMID: 25792514 DOI: 10.1159/000373971]
- 54 **Tan M**, Schmidt RH, Beier JL, Watson WH, Zhong H, States JC, Arteel GE. Chronic subhepatotoxic exposure to arsenic enhances hepatic injury caused by high fat diet in mice. *Toxicol Appl Pharmacol* 2011; **257**: 356-364 [PMID: 21983427 DOI: 10.1016/j.taap.2011.09.019]
- 55 **Osakabe N**, Takano H, Sanbongi C, Yasuda A, Yanagisawa R, Inoue K, Yoshikawa T. Anti-inflammatory and anti-allergic effect of rosmarinic acid (RA); inhibition of seasonal allergic rhinoconjunctivitis (SAR) and its mechanism. *Biofactors* 2004; **21**: 127-131 [PMID: 15630183]
- 56 **Fei M**, Xie Q, Zou Y, He R, Zhang Y, Wang J, Bo L, Li J, Deng X. Alpha-lipoic acid protects mice against concanavalin A-induced hepatitis by modulating cytokine secretion and reducing reactive oxygen species generation. *Int Immunopharmacol* 2016; **35**: 53-60 [PMID: 27018751 DOI: 10.1016/j.intimp.2016.03.023]
- 57 **Ji YR**, Kim HJ, Yu DH, Bae KB, Park SJ, Park SJ, Jang WY, Kang MC, Jeong J, Sung YH, Choi M, Park T, Park T, Yun JW, Lee HS, Lee S, Kim MO, Ryoo ZY. Over-expression of Roquin aggravates T cell mediated hepatitis in transgenic mice using T cell specific promoter. *Biochem Biophys Res Commun* 2014; **452**: 822-827 [PMID: 25201726 DOI: 10.1016/j.bbrc.2014.09.001]
- 58 **Pratap UP**, Sharma HR, Mohanty A, Kale P, Gopinath S, Hima L, Priyanka HP, ThyagaRajan S. Estrogen upregulates inflammatory signals through NF- κ B, IFN- γ , and nitric oxide via Akt/mTOR pathway in the lymph node lymphocytes of middle-aged female rats. *Int Immunopharmacol* 2015; **29**: 591-598 [PMID: 26440402 DOI: 10.1016/j.intimp.2015.09.024]
- 59 **Nakamura K**, Ito T, Yoneda M, Takamoto S, Nakade Y, Okamoto S, Okada M, Yokohama S, Aso K, Makino I. Antithrombin III prevents concanavalin A-induced liver injury through inhibition of macrophage inflammatory protein-2 release and production of prostacyclin in mice. *J Hepatol* 2002; **36**: 766-773 [PMID: 12044526]
- 60 **Muruve DA**, Barnes MJ, Stillman IE, Libermann TA. Adenoviral gene therapy leads to rapid induction of multiple chemokines and acute neutrophil-dependent hepatic injury in vivo. *Hum Gene Ther* 1999; **10**: 965-976 [PMID: 10223730 DOI: 10.1089/10430349950018364]
- 61 **Ebe Y**, Hasegawa G, Takatsuka H, Umezaki H, Mitsuyama M, Arakawa M, Mukaida N, Naito M. The role of Kupffer cells and regulation of neutrophil migration into the liver by macrophage inflammatory protein-2 in primary listeriosis in mice. *Pathol Int* 1999; **49**: 519-532 [PMID: 10469395]
- 62 **Tirosh O**, Artan A, Aharoni-Simon M, Ramadori G, Madar Z. Impaired liver glucose production in a murine model of steatosis and endotoxemia: protection by inducible nitric oxide synthase. *Antioxid Redox Signal* 2010; **13**: 13-26 [PMID: 19951063 DOI: 10.1089/ars.2009.2789]
- 63 **Baggiolini M**. Chemokines and leukocyte traffic. *Nature* 1998; **392**: 565-568 [PMID: 9560152 DOI: 10.1038/33340]
- 64 **Malik IA**, Moriconi F, Sheikh N, Naz N, Khan S, Dudas J, Mansuroglu T, Hess CF, Rave-Fränk M, Christiansen H, Ramadori G. Single-dose gamma-irradiation induces up-regulation of chemokine gene expression and recruitment of granulocytes into the portal area but not into other regions of rat hepatic tissue. *Am J Pathol* 2010; **176**: 1801-1815 [PMID: 20185578 DOI: 10.2353/ajpath.2010.090505]

- 65 **Li X**, Klintman D, Sato T, Hedlund G, Schramm R, Jeppsson B, Thorlacius H. Interleukin-10 mediates the protective effect of Linomide by reducing CXC chemokine production in endotoxin-induced liver injury. *Br J Pharmacol* 2004; **143**: 865-871 [PMID: 15492015 DOI: 10.1038/sj.bjp.0706015]
- 66 **Massey VL**, Poole LG, Siow DL, Torres E, Warner NL, Schmidt RH, Ritzenthaler JD, Roman J, Arteel GE. Chronic Alcohol Exposure Enhances Lipopolysaccharide-Induced Lung Injury in Mice: Potential Role of Systemic Tumor Necrosis Factor-Alpha. *Alcohol Clin Exp Res* 2015; **39**: 1978-1988 [PMID: 26380957 DOI: 10.1111/acer.12855]
- 67 **Dong W**, Simeonova PP, Gallucci R, Matheson J, Fannin R, Montuschi P, Flood L, Luster MI. Cytokine expression in hepatocytes: role of oxidant stress. *J Interferon Cytokine Res* 1998; **18**: 629-638 [PMID: 9726445 DOI: 10.1089/jir.1998.18.629]
- 68 **Pennington HL**, Wilce PA, Worrall S. Chemokine and cell adhesion molecule mRNA expression and neutrophil infiltration in lipopolysaccharide-induced hepatitis in ethanol-fed rats. *Alcohol Clin Exp Res* 1998; **22**: 1713-1718 [PMID: 9835285]
- 69 **Schmid A**, Kopp A, Hanses F, Karrasch T, Schäffler A. C1q/TNF-related protein-3 (CTRP-3) attenuates lipopolysaccharide (LPS)-induced systemic inflammation and adipose tissue Erk-1/-2 phosphorylation in mice in vivo. *Biochem Biophys Res Commun* 2014; **452**: 8-13 [PMID: 24996172 DOI: 10.1016/j.bbrc.2014.06.054]
- 70 **Reynaert NL**, van der Vliet A, Guala AS, McGovern T, Hristova M, Pantano C, Heintz NH, Heim J, Ho YS, Matthews DE, Wouters EF, Janssen-Heininger YM. Dynamic redox control of NF-kappaB through glutaredoxin-regulated S-glutathionylation of inhibitory kappaB kinase beta. *Proc Natl Acad Sci USA* 2006; **103**: 13086-13091 [PMID: 16916935 DOI: 10.1073/pnas.0603290103]
- 71 **Cuaz-Pérolin C**, Billiet L, Bauge E, Copin C, Scott-Algara D, Genze F, Büchele B, Syrovets T, Simmet T, Rouis M. Antiinflammatory and antiatherogenic effects of the NF-kappaB inhibitor acetyl-11-keto-beta-boswellic acid in LPS-challenged ApoE-/- mice. *Arterioscler Thromb Vasc Biol* 2008; **28**: 272-277 [PMID: 18032778 DOI: 10.1161/atvbaha.107.155606]
- 72 **Sasakawa Y**, Kominami A, Yamamoto K, Nakaoka F, Nakamura M, Nakao M, Abe M, Fukuhama C, Kagawa K. Effects of globin digest and its active ingredient Trp-Thr-Gln-Arg on galactosamine/lipopolysaccharide-induced liver injury in ICR mice. *Life Sci* 2012; **90**: 190-199 [PMID: 22154906 DOI: 10.1016/j.lfs.2011.11.013]
- 73 **Dorman RB**, Gujral JS, Bajt ML, Farhood A, Jaeschke H. Generation and functional significance of CXC chemokines for neutrophil-induced liver injury during endotoxemia. *Am J Physiol Gastrointest Liver Physiol* 2005; **288**: G880-G886 [PMID: 15576625 DOI: 10.1152/ajpgi.00317.2004]
- 74 **Li X**, Klintman D, Liu Q, Sato T, Jeppsson B, Thorlacius H. Critical role of CXC chemokines in endotoxemic liver injury in mice. *J Leukoc Biol* 2004; **75**: 443-452 [PMID: 14673016 DOI: 10.1189/jlb.0603297]
- 75 **Martius G**, Alwahsh SM, Rave-Fränk M, Hess CF, Christiansen H, Ramadori G, Malik IA. Hepatic fat accumulation and regulation of FAT/CD36: an effect of hepatic irradiation. *Int J Clin Exp Pathol* 2014; **7**: 5379-5392 [PMID: 25197426]
- 76 **Cameron S**, Schwartz A, Sultan S, Schaefer IM, Hermann R, Rave-Fränk M, Hess CF, Christiansen H, Ramadori G. Radiation-induced damage in different segments of the rat intestine after external beam irradiation of the liver. *Exp Mol Pathol* 2012; **92**: 243-258 [PMID: 22227376 DOI: 10.1016/j.yexmp.2011.11.007]
- 77 **Mukhopadhyay P**, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian G, Gao RY, Patel V, Wink DA, Liaudet L, Haskó G, Mechoulam R, Pacher P. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. *Free Radic Biol Med* 2011; **50**: 1368-1381 [PMID: 21362471 DOI: 10.1016/j.freeradbiomed.2011.02.021]
- 78 **Ouzounidis N**, Giakoustidis A, Poutahidis T, Angelopoulou K, Iliadis S, Chatzigiagkos A, Zacharioudaki A, Angelopoulos S, Papalois A, Papanikolaou V, Giakoustidis D. Interleukin 18 binding protein ameliorates ischemia/reperfusion-induced hepatic injury in mice. *Liver Transpl* 2016; **22**: 237-246 [PMID: 26479304 DOI: 10.1002/lt.24359]
- 79 **Stewart RK**, Dangi A, Huang C, Murase N, Kimura S, Stolz DB, Wilson GC, Lentsch AB, Gandhi CR. A novel mouse model of depletion of stellate cells clarifies their role in ischemia/reperfusion- and endotoxin-induced acute liver injury. *J Hepatol* 2014; **60**: 298-305 [PMID: 24060854 DOI: 10.1016/j.jhep.2013.09.013]
- 80 **Kim HY**, Kim SJ, Lee SM. Activation of NLRP3 and AIM2 inflammasomes in Kupffer cells in hepatic ischemia/reperfusion. *FEBS J* 2015; **282**: 259-270 [PMID: 25327779 DOI: 10.1111/febs.13123]
- 81 **Ocuin LM**, Zeng S, Cavnar MJ, Sorenson EC, Bamboat ZM, Greer JB, Kim TS, Popow R, DeMatteo RP. Nilotinib protects the murine liver from ischemia/reperfusion injury. *J Hepatol* 2012; **57**: 766-773 [PMID: 22641092 DOI: 10.1016/j.jhep.2012.05.012]
- 82 **Monson KM**, Dowlatshahi S, Crockett ET. CXC-chemokine regulation and neutrophil trafficking in hepatic ischemia-reperfusion injury in P-selectin/ICAM-1 deficient mice. *J Inflamm (Lond)* 2007; **4**: 11 [PMID: 17524141 DOI: 10.1186/1476-9255-4-11]
- 83 **Yoshidome H**, Kato A, Edwards MJ, Lentsch AB. Interleukin-10 suppresses hepatic ischemia/reperfusion injury in mice: implications of a central role for nuclear factor kappaB. *Hepatology* 1999; **30**: 203-208 [PMID: 10385657 DOI: 10.1002/hep.510300120]
- 84 **Kuboki S**, Sakai N, Clarke C, Schuster R, Blanchard J, Edwards MJ, Lentsch AB. The peptidyl-prolyl isomerase, Pin1, facilitates NF-kappaB binding in hepatocytes and protects against hepatic ischemia/reperfusion injury. *J Hepatol* 2009; **51**: 296-306 [PMID: 19515451 DOI: 10.1016/j.jhep.2009.04.016]
- 85 **Alwahsh SM**, Xu M, Schultze FC, Wilting J, Mihm S, Raddatz D, Ramadori G. Combination of alcohol and fructose exacerbates metabolic imbalance in terms of hepatic damage, dyslipidemia, and insulin resistance in rats. *PLoS One* 2014; **9**: e104220 [PMID: 25101998 DOI: 10.1371/journal.pone.0104220]
- 86 **Mathews S**, Feng D, Maricic I, Ju C, Kumar V, Gao B. Invariant natural killer T cells contribute to chronic-plus-binge ethanol-mediated liver injury by promoting hepatic neutrophil infiltration. *Cell Mol Immunol* 2016; **13**: 206-216 [PMID: 25661730 DOI: 10.1038/cmi.2015.06]
- 87 **Pritchard MT**, Nagy LE. Ethanol-induced liver injury: potential roles for egr-1. *Alcohol Clin Exp Res* 2005; **29**: 146S-150S [PMID: 16344600]
- 88 **Budick-Harmelin N**, Dudas J, Demuth J, Madar Z, Ramadori G, Tirosh O. Triglycerides potentiate the inflammatory response in rat Kupffer cells. *Antioxid Redox Signal* 2008; **10**: 2009-2022 [PMID: 18710323 DOI: 10.1089/ars.2007.1876]
- 89 **Bautista AP**. Acute ethanol binge followed by withdrawal regulates production of reactive oxygen species and cytokine-induced neutrophil chemoattractant and liver injury during reperfusion after hepatic ischemia. *Antioxid Redox Signal* 2002; **4**: 721-731 [PMID: 12470499 DOI: 10.1089/152308602760598864]
- 90 **Nanji AA**, Jokelainen K, Fotouhinia M, Rahemtulla A, Thomas P, Tipoe GL, Su GL, Dannenberg AJ. Increased severity of alcoholic liver injury in female rats: role of oxidative stress, endotoxin, and chemokines. *Am J Physiol Gastrointest Liver Physiol* 2001; **281**: G1348-G1356 [PMID: 11705739]
- 91 **Nanji AA**, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in rats by inhibiting the expression of NF-kappa B-dependent genes. *Am J Physiol Gastrointest Liver Physiol* 2003; **284**: G321-G327 [PMID: 12388178 DOI: 10.1152/ajpgi.00230.2002]
- 92 **Jayaraman J**, Jesudoss VA, Menon VP, Namasivayam N. Anti-inflammatory role of naringenin in rats with ethanol induced liver injury. *Toxicol Mech Methods* 2012; **22**: 568-576 [PMID: 22900548 DOI: 10.3109/15376516.2012.707255]
- 93 **Savransky V**, Bevens S, Nanayakkara A, Li J, Smith PL, Torbenson MS, Polotsky VY. Chronic intermittent hypoxia causes

- hepatitis in a mouse model of diet-induced fatty liver. *Am J Physiol Gastrointest Liver Physiol* 2007; **293**: G871-G877 [PMID: 17690174 DOI: 10.1152/ajpgi.00145.2007]
- 94 **Zampetaki A**, Mitsialis SA, Pfeilschifter J, Kourembanas S. Hypoxia induces macrophage inflammatory protein-2 (MIP-2) gene expression in murine macrophages via NF-kappaB: the prominent role of p42/ p44 and PI3 kinase pathways. *FASEB J* 2004; **18**: 1090-1092 [PMID: 15132979 DOI: 10.1096/fj.03-0991fje]
- 95 **Ren X**, Carpenter A, Hogaboam C, Colletti L. Mitogenic properties of endogenous and pharmacological doses of macrophage inflammatory protein-2 after 70% hepatectomy in the mouse. *Am J Pathol* 2003; **163**: 563-570 [PMID: 12875976 DOI: 10.1016/s0002-9440(10)63684-x]
- 96 **Hogaboam CM**, Simpson KJ, Chensue SW, Steinhauser ML, Lukacs NW, Gauldie J, Strieter RM, Kunkel SL. Macrophage inflammatory protein-2 gene therapy attenuates adenovirus- and acetaminophen-mediated hepatic injury. *Gene Ther* 1999; **6**: 573-584 [PMID: 10476217 DOI: 10.1038/sj.gt.3300858]
- 97 **Hogaboam CM**, Bone-Larson CL, Steinhauser ML, Lukacs NW, Colletti LM, Simpson KJ, Strieter RM, Kunkel SL. Novel CXCR2-dependent liver regenerative qualities of ELR-containing CXC chemokines. *FASEB J* 1999; **13**: 1565-1574 [PMID: 10463948]
- 98 **Hogaboam CM**, Bone-Larson CL, Steinhauser ML, Matsukawa A, Gosling J, Boring L, Charo IF, Simpson KJ, Lukacs NW, Kunkel SL. Exaggerated hepatic injury due to acetaminophen challenge in mice lacking C-C chemokine receptor 2. *Am J Pathol* 2000; **156**: 1245-1252 [PMID: 10751350 DOI: 10.1016/s0002-9440(10)64995-4]
- 99 **Wilson GC**, Kuboki S, Freeman CM, Nojima H, Schuster RM, Edwards MJ, Lentsch AB. CXC chemokines function as a rheostat for hepatocyte proliferation and liver regeneration. *PLoS One* 2015; **10**: e0120092 [PMID: 25756662 DOI: 10.1371/journal.pone.0120092]
- 100 **Du J**, Luan J, Liu H, Daniel TO, Peiper S, Chen TS, Yu Y, Horton LW, Nanney LB, Strieter RM, Richmond A. Potential role for Duffy antigen chemokine-binding protein in angiogenesis and maintenance of homeostasis in response to stress. *J Leukoc Biol* 2002; **71**: 141-153 [PMID: 11781390]
- 101 **Kollmar O**, Junker B, Rupertus K, Scheuer C, Menger MD, Schilling MK. Liver resection-associated macrophage inflammatory protein-2 stimulates engraftment but not growth of colorectal metastasis at extrahepatic sites. *J Surg Res* 2008; **145**: 295-302 [PMID: 17561115 DOI: 10.1016/j.jss.2007.02.010]
- 102 **Kollmar O**, Menger MD, Schilling MK. Macrophage inflammatory protein-2 contributes to liver resection-induced acceleration of hepatic metastatic tumor growth. *World J Gastroenterol* 2006; **12**: 858-867 [PMID: 16521212 DOI: 10.3748/wjg.v12.i6.858]
- 103 **Shayakhmetov DM**, Li ZY, Ni S, Lieber A. Interference with the IL-1-signaling pathway improves the toxicity profile of systemically applied adenovirus vectors. *J Immunol* 2005; **174**: 7310-7319 [PMID: 15905578]
- 104 **Jaeschke H**. Inflammation in response to hepatocellular apoptosis. *Hepatology* 2002; **35**: 964-966 [PMID: 11915046 DOI: 10.1053/jhep.2002.0350964]
- 105 **Kawamura H**, Kawamura T, Kanda Y, Kobayashi T, Abo T. Extracellular ATP-stimulated macrophages produce macrophage inflammatory protein-2 which is important for neutrophil migration. *Immunology* 2012; **136**: 448-458 [PMID: 22564028 DOI: 10.1111/j.1365-2567.2012.03601.x]
- 106 **O'Brien KM**, Allen KM, Rockwell CE, Towery K, Luyendyk JP, Copple BL. IL-17A synergistically enhances bile acid-induced inflammation during obstructive cholestasis. *Am J Pathol* 2013; **183**: 1498-1507 [PMID: 24012680 DOI: 10.1016/j.ajpath.2013.07.019]
- 107 **Tang H**, Amara U, Tang D, Barnes MA, McDonald C, Nagy LE. Synergistic interaction between C5a and NOD2 signaling in the regulation of chemokine expression in RAW 264.7 macrophages. *Adv Biosci Biotechnol* 2013; **4**: 30-37 [PMID: 24634797 DOI: 10.4236/abb.2013.48A3004]
- 108 **Colletti LM**, Green ME, Burdick MD, Strieter RM. The ratio of ELR+ to ELR- CXC chemokines affects the lung and liver injury following hepatic ischemia/ reperfusion in the rat. *Hepatology* 2000; **31**: 435-445 [PMID: 10655268 DOI: 10.1002/hep.510310225]
- 109 **Colletti LM**, Cortis A, Lukacs N, Kunkel SL, Green M, Strieter RM. Tumor necrosis factor up-regulates intercellular adhesion molecule 1, which is important in the neutrophil-dependent lung and liver injury associated with hepatic ischemia and reperfusion in the rat. *Shock* 1998; **10**: 182-191 [PMID: 9744646]

P- Reviewer: Erin N, Karmouty-Quintana H **S- Editor:** Yu J

L- Editor: A **E- Editor:** Zhang FF





Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: <http://www.f6publishing.com/helpdesk>
<http://www.wjgnet.com>



ISSN 1007-9327

